MASH - Metabolic Dysfunction-Associated Steatohepatitis
Infectious Diseases
2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2025
2026
2027
2028
2029
2030
Chipscreen BiosciencesChiglitazar Placebo
Madrigal PharmaceuticalsResmetirom
Clinical Trials (2)
Total enrollment: 120 patients across 2 trials
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus
Start: Jan 2026Est. completion: Dec 2030
Phase 2Not Yet Recruiting
Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Start: Dec 2025Est. completion: Dec 2027120 patients
Phase 2Active Not Recruiting
Related Jobs in Infectious Diseases
Senior Associate Scientist (contract), Upstream Polysaccharide Process Development
VaxCyte
San Carlos, California, United States
6h ago
$56/hr
Senior Associate Scientist (contract), Polysaccharide Analytical Development
VaxCyte
San Carlos, California, United States
6h ago
$56/hr
Director, Program Management
Metaphore Biotechnologies
Somerville, MA USA
10h ago
$179K - $237K/yr
First Line Sales Leader (Medan)
GSK
Indonesia - Sumatera Utara
23h ago
General Worker
GSK
Pakistan - Sindh - Karachi
23h ago
Vaccine Business Manager (Jakarta)
GSK
Indonesia - DKI Jakarta
23h ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space